leishmania vaccine (ChAd63-KH) / York University, Kenya Medical Research Institute - LARVOL DELTA

Advances in Leishmania Vaccines: Current Development and Future Prospects. (PubMed, Pathogens) - "Despite some success and years of effort, human vaccine trials have encountered difficulties in conferring durable protection against Leishmania, a problem that may be attributed to the parasite's antigenic diversity and the intricate nature of the host's immune response. The aim of this review is to provide a thorough overview of recent advances in Leishmania vaccine development, ranging from initial trials to recent achievements, such as the ChAd63-KH DNA vaccine, which underscores the potential for effective control of leishmaniasis through continued research in this field."

Journal • Review • Infectious Disease • IL12A

A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis. (PubMed, Mol Ther Methods Clin Dev) - P2b | "Whole-blood transcriptomic analysis identified transcriptional modules associated with interferon responses and monocyte and dendritic cell activation. Thus, a single vaccination with ChAd63-KH showed no therapeutic efficacy in this subset of Sudanese patients with PKDL."

Clinical • Journal • P2b data • Infectious Disease

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis. (PubMed, Wellcome Open Res) - P2b | "If therapeutic benefit of ChAd63-KH can be shown in PKDL further evaluation of the vaccine in other forms of leishmaniasis should be considered. Clinicaltrials.gov registration: NCT03969134."

Journal • P2b data • Dermatology • Human Immunodeficiency Virus • Infectious Disease

A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL (clinicaltrials.gov) - P2b | N=86 | Completed | Sponsor: University of York | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • IFNG